Skip to main content
| News

Investors top up capital of BioVersys

09.06.2022

BioVersys has raised 24.2 million Swiss francs in a series C funding round. The Basel-based pharmaceutical company plans to use this to develop a clinical pipeline of innovative therapies to combat antibiotic resistance and for targeted microbiome modulation.

BioVersys has received 24.2 million Swiss francs from investors in a series C funding round. According to an announcement from the pharmaceutical company, it will use the funds to start the first phase II clinical trials for two drug candidates as well as preclinical development of a third active substance. BioVersys focuses on the research and development of therapies to combat life-threatening, multidrug-resistant (MDR) bacterial infections (caused by antimicrobial resistance; AMR) and targeted modulation of the microbiome.

The Basel-based company is developing a new, award-winning class of therapeutic agents called TRICs (transcriptional regulator inhibiting compounds). These drugs are able to simply eliminate bacterial resistance. Administering this proprietary invention from BioVersys together with existing antibiotics restores the efficacy of these antibiotics.

Preventing future pandemics

BioVersys’ CEO Dr. Marc Gitzinger comments: “We are grateful to the unwavering commitment of our knowledgeable long-term investors and welcome a number of new investors that understand the need for clinically meaningful solutions to address the burgeoning AMR crisis.”

Chairman of the Board Dr. Seng Chin Mah views the area of antibiotic resistance as “an attractive investment opportunity for strategic investors who are looking to impact global healthcare by preventing future pandemics, ensuring availability of pandemic-relevant drugs and participating in the upside potential of a changing regulatory and market environment.” He adds that BioVersys is “clearly one of the most compelling players” in this regard.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

KUORI developing biodegradable plastics
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Cell and gene therapies gain momentum in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
AMR Action Fund invests in new antibiotics developed by BioVersys
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Investors give Resistell 8.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.